DEUTSCHE BANK AG\ - BRAINSTORM CELL THERAPEUTICS ownership

BRAINSTORM CELL THERAPEUTICS's ticker is BCLI and the CUSIP is 10501E201. A total of 94 filers reported holding BRAINSTORM CELL THERAPEUTICS in Q4 2020. The put-call ratio across all filers is 1.49 and the average weighting 0.0%.

Quarter-by-quarter ownership
DEUTSCHE BANK AG\ ownership history of BRAINSTORM CELL THERAPEUTICS
ValueSharesWeighting
Q3 2021$7,000
-12.5%
2,1000.0%0.00%
Q2 2021$8,000
-89.9%
2,100
-89.8%
0.00%
Q1 2021$79,000
-17.7%
20,678
-2.7%
0.00%
Q4 2020$96,000
-63.8%
21,249
+35.5%
0.00%
Q3 2020$265,000
+73.2%
15,683
+15.0%
0.00%
Q2 2020$153,000
+920.0%
13,640
+286.8%
0.00%
Q4 2019$15,000
-84.0%
3,526
-88.2%
0.00%
Q1 2018$94,000
-75.6%
29,912
-69.7%
0.00%
Q4 2017$386,000
+310.6%
98,590
+330.0%
0.00%
Q3 2017$94,00022,9260.00%
Other shareholders
BRAINSTORM CELL THERAPEUTICS shareholders Q4 2020
NameSharesValueWeighting ↓
ABNER HERRMAN & BROCK LLC 241,500$1,093,0000.17%
OCCUDO QUANTITATIVE STRATEGIES LP 90,584$410,0000.13%
EPIQ PARTNERS, LLC 10,550$48,0000.03%
Phoenix Holdings Ltd. 173,683$799,0000.02%
JACOB ASSET MANAGEMENT OF NEW YORK LLC 5,500$25,0000.02%
CFO4Life Group, LLC 12,003$54,0000.02%
HighPoint Advisor Group LLC 15,733$115,0000.01%
VOLORIDGE INVESTMENT MANAGEMENT, LLC 357,761$1,619,0000.01%
Virtu Financial LLC 24,484$111,0000.01%
ETF MANAGERS GROUP, LLC 93,902$435,0000.01%
View complete list of BRAINSTORM CELL THERAPEUTICS shareholders